Today’s biggest challenge for pharma is securing an adequate pipeline of innovative products. So, when an asset in development seems promising, it is vital to maximize its value. Choices are expensive and outcomes are uncertain, especially in new areas with competitors racing you to the launch pad. EVERSANA’s consultants help frame the challenge, develop the options and value the asset under different scenarios, leading to clarity of trade-offs and quality decisions.
- 资产发展战略：确定和评估不同试验选择下的 TPP，结合决策分析和财务分析，权衡风险和回报，确定最佳发展路径
- 资产商业战略: Positioning, landscape and competitive analysis including, regulatory and pricing uncertainties, to make the most of an in-market asset
- 资产估值：如果资产是许可、合作或直接销售协议的标的资产，则使用结合概率和不确定事件的估值方法提供谈判支持，以在各种情况下得出明确的价值
- Loss of Exclusivity：如果资产在丧失独有权后面临仿制药品的竞争，那么可以在经过严格评估的创造性方法中选择定价、战斗品牌和/或合作方式等，以尽量维持价值
We have supported many clients, from smaller to multinational pharma and MedTech companies, across the Europe markets in obtaining the highest value from choosing the right path for their individual assets.